Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Mar 30:5:16020.
doi: 10.1038/mtm.2016.20. eCollection 2016.

In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application

Graça Almeida-Porada  1 , Anthony Atala  1 , Christopher D Porada  1
Affiliations
Review

In utero stem cell transplantation and gene therapy: rationale, history, and recent advances toward clinical application

Graça Almeida-Porada et al. Mol Ther Methods Clin Dev. .

Abstract

Recent advances in high-throughput molecular testing have made it possible to diagnose most genetic disorders relatively early in gestation with minimal risk to the fetus. These advances should soon allow widespread prenatal screening for the majority of human genetic diseases, opening the door to the possibility of treatment/correction prior to birth. In addition to the obvious psychological and financial benefits of curing a disease in utero, and thereby enabling the birth of a healthy infant, there are multiple biological advantages unique to fetal development, which provide compelling rationale for performing potentially curative treatments, such as stem cell transplantation or gene therapy, prior to birth. Herein, we briefly review the fields of in utero transplantation (IUTx) and in utero gene therapy and discuss the biological hurdles that have thus far restricted success of IUTx to patients with immunodeficiencies. We then highlight several recent experimental breakthroughs in immunology, hematopoietic/marrow ontogeny, and in utero cell delivery, which have collectively provided means of overcoming these barriers, thus setting the stage for clinical application of these highly promising therapies in the near future.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overview of hematopoietic and immune events impacting IUTx and IUGT.
See this image and copyright information in PMC

References

    1. Harrison, MR, Golbus, MS, Filly, RA, Callen, PW, Katz, M, de Lorimier, AA et al. (1982). Fetal surgery for congenital hydronephrosis. N Engl J Med 306: 591–593. - PubMed
    1. Pearson, EG and Flake, AW (2013). Stem cell and genetic therapies for the fetus. Semin Pediatr Surg 22: 56–61. - PubMed
    1. McClain, LE and Flake, AW (2016). In utero stem cell transplantation and gene therapy: recent progress and the potential for clinical application. Best Pract Res Clin Obstet Gynaecol 31: 88–98. - PubMed
    1. Vrecenak, JD and Flake, AW (2013). In utero hematopoietic cell transplantation–recent progress and the potential for clinical application. Cytotherapy 15: 525–535. - PubMed
    1. Shizuru, JA, Negrin, RS and Weissman, IL (2005). Hematopoietic stem and progenitor cells: clinical and preclinical regeneration of the hematolymphoid system. Annu Rev Med 56: 509–538. - PubMed